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Central nervous system (CNS) involvement in adult acute myeloid leukemia (AML) is rare and associated with
poor outcomes. Therefore, CNS involvement in AML is an indicator for allogeneic hematopoietic stem cell
transplantation (allo-HSCT). However, the impact of CNS involvement in AML on the outcome of allo-HSCT
remains unclear. We performed a large-scale nationwide retrospective analysis to elucidate the outcomes
of allo-HSCT on AML with CNS involvement (CNSþAML). Clinical data were collected from a registry database
of the Japan Society for Hematopoietic Cell Transplantation. CNS involvement was deﬁned as the inﬁltration
of leukemia cells into the CNS or myeloid sarcoma in the CNS identiﬁed at any time from diagnosis to
transplantation. One hundred ﬁfty-seven patients with CNSþAML underwent allo-HSCT between 2006 and
2011. The estimated overall survival, cumulative incidence of relapse and nonrelapse mortality at 2 years for
CNSþAML (51.2%, 30.2%, and 14.5%, respectively) were comparable with those for AML without CNS
involvement (48.6%, 27.4%, and 22.0%, respectively). Univariate and multivariate analyses indicated that the
development of chronic graft-versus-host disease, disease status, and cytogenetic risk category were inde-
pendent prognostic factors for overall survival for CNSþAML. These results suggest that allo-HSCT may
improve outcomes in patients with CNSþAML.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Central nervous system (CNS) involvement in acute
myeloid leukemia (AML) is a rare complication, occurring
in 2% to 5% of patients at the time of AML diagnosis
[1,2]. Predisposing factors for AML with CNS involvementdgments on page 2032.
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ty for Blood and Marrow Transplantation.(CNSþAML) include higher level of lactate dehydrogenase
and WBC counts at diagnosis, chromosome 16 inversion and
chromosome 11 abnormality, French-American-British (FAB)
subgroup M4 and M5, and younger age [3-5].
Outcomes for patients with CNSþAML are poor [5,6], and
optimal treatment is yet to be established, mainly because of
the rarity of this condition. Although conventional therapy,
such as intrathecal chemotherapy with methotrexate and/or
cytarabine, irradiation, and systemic chemotherapy with
high-dose cytarabine, are effective, the remission duration is
short and relapse rate is high [5-7]. Dekker et al. [8] reported
Table 1
Patient Characteristic
CNSþAML CNSeAML P
Median age, yr (range) 45 (17-68) 50 (16-82) <.001
<50 99 (63.1%) 2434 (49.6%)
50 58 (36.9%) 2477 (50.6%) <.001
Gender
Male 109 (69.4%) 2877 (58.6%)
Female 48 (30.6%) 2034 (41.4%) .006
Disease status
CR 66 (42.0%) 2602 (53.0%)
Non-CR 91 (58.0%) 2308 (47.0%) .007
Donor source
Related 40 (25.5%) 1557 (31.7%)
Unrelated BM/PB 75 (47.8%) 1959 (39.9%)
Unrelated CB 42 (26.8%) 1385 (28.2%) .123
Serological HLA match
Match 95 (60.5%) 2851 (58.1%)
Mismatch 62 (39.5%) 2045 (41.6%) .622
Conditioning
TBI-based MAC 88 (56.1%) 1992 (40.6%)
NoneTBI-based MAC 29 (18.5%) 1273 (25.9%)
RIC 40 (25.5%) 1624 (33.1%) <.001
Performance status
0, 1 125 (79.6%) 4360 (88.8%)
2-4 31 (19.7%) 523 (10.6%) .001
Cytogenetic risk category
Favorable 34 (21.7%) 544 (11.1%)
Intermediate 62 (39.5%) 2287 (46.6%)
Unfavorable 55 (35.0%) 1485 (30.2%)
Unknown 4 (2.5%) 465 (9.5%) <.001
FAB classiﬁcation
M4/5 67 (42.7%) 1100 (22.4%)
Other 84 (53.5%) 3395 (69.1%) <.001
BM indicates bone marrow; PB, peripheral blood; CB, cord blood; MA,
myeloablative conditioning; RIC, reduced-intensity conditioning.
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about 10 months without allogeneic hematopoietic stem cell
transplantation (allo-HSCT). Therefore, allo-HSCT is consid-
ered optimal for patients with CNSþAML. However, the
impact of CNS involvement on the outcomes after allo-HSCT
remains unclear. Therefore, we conducted a nationwide
retrospective study to examine the outcome of patients with
CNSþAML who underwent allo-HSCT.
METHODS
Study Population
Clinical data were collected from the registry database of the Japan
Society for Hematopoietic Cell Transplantation. Patients with AML
(excluding acute promyelocytic leukemia) older than age 15 years who
underwent allo-HSCT for the ﬁrst time between January 2006 and
December 2011 were extracted from the database. We retrospectively
analyzed the clinical features and the outcome of patients with CNSþAML.
Outcomes after allo-HSCT for patients with CNSþAML were compared with
those of patients with AML without CNS involvement (CNSeAML), and
prognosis factors for overall survival (OS) in patients with CNSþAML were
examined. This study was approved by the Institutional Review Board of the
Tokyo Metropolitan Otsuka Hospital.
Statistical Analysis
OS was deﬁned as the number of days from allo-HSCT until death from
any cause. The incidence of relapse was deﬁned as the number of days from
allo-HSCT to relapse of the underlying disease. Nonrelapse mortality (NRM)
was deﬁned as the number of days from allo-HSCT to death without relapse.
Any patient who was alive at the last follow-up date was censored. OS and
NRM were analyzed in all patients, and relapse was analyzed in patients
who achieved complete remission (CR).
CNS involvement was deﬁned as inﬁltration of leukemia cells into the
CNS or myeloid sarcoma in the CNS, as identiﬁed at any time from diagnosis
to transplantation. Patients with other concurrent extramedullary disease
were included.
The myeloablative conditioning (MAC) regimen was classiﬁed as either
total body irradiation (TBI) >8 Gy or regimens containing oral busulfan
9 mg/kg (or intravenous injection in equivalent doses) or melphalan
>140 mg/m2. Other regimens were classiﬁed as reduced-intensity condi-
tioning [9]. Cytogenetic subgroups were classiﬁed according to the South-
west Oncology Group deﬁnition [10]. HLA mismatch was deﬁned as
incompatibility between the recipient and donor when at least a 1-antigen
mismatch was detected at the serological level of HLA-A, -B, or -DR.
Fisher’s exact test and theMann-Whitney test were used for comparison
of categorical and continuous variables, respectively. OS was estimated by
the Kaplan-Meier method and was compared using a log-rank test. Relapse
and NRM were considered competing risk events for each other and were
compared using Gray’s test. The Cox proportional hazardmodel was used for
multivariate analysis of prognostic factors. Covariates found to be signiﬁcant
in univariate analysis (P < .1) were included in the model. The following
variables were compared in univariate analysis: age at allo-HSCT, gender,
donor source, serological HLA mismatch, donorerecipient gender
mismatch, gender, ABO mismatch, FAB classiﬁcation (M4/M5 or others) and
conditioning regimen (noneTBI-based MAC, TBI-based MAC, or reduced-
intensity conditioning), Eastern Cooperative Oncology Group performance
status, cytogenetic risk category, and incidence of acute or chronic
graft-versus-host disease (GVHD). The impact of chronic GVHD on other
outcomes was always studied as a time-dependent variable. P values were
2-sided, and differences were considered to be statistically signiﬁcant when
P < .05. All statistical analyses were performed using EZR (R version 2.13.0
[11].
RESULTS
Patient Characteristics
Of the 5068 AML patients who underwent ﬁrst allo-HSCT,
157 patients were CNSþAML and 4911 patients were
CNSeAML. Table 1 shows their clinical characteristics. The
median age was lower and the proportion of male patients
was higher in the CNSþAML group than in the CNSeAML
group. A higher proportion of patients had non-CR disease
status and worse Eastern Cooperative Oncology Group per-
formance status at allo-HSCT in the CNSþAML group than in
the CNSeAML group. The proportion of patients receiving
TBI-based MAC regimens was higher in the CNSþAML groupthan in the CNSeAML group. The incidence of favorable
cytogenetic risk category and M4/M5 FAB classiﬁcation was
higher in the CNSþAML group than in the CNSeAML group.
Transplantation Outcomes of the CNSþAML Group and
CNSeAML Group
The probability of OS was comparable in the CNSþAML
group and the CNSeAML group (2-year OS rates in the
CNSþAML group and the CNSeAML group were 51.2% and
48.6%, respectively [P ¼ .847]; Figure 1A). Subgroup analysis
according to age, disease status, and cytogenetic risk cate-
gory was performed. The probability of OS in the CNSþAML
group and the CNSeAML group was similar in both patients
younger than 50 years and patients aged 50 years or older
(Figure 1B), in both patients with CR and non-CR at the time
of allo-HSCT (Figure 1C), and in patients with all cytogenetic
risk categories (Supplemental Figure 1). The cumulative
incidence of relapse and NRMwere not signiﬁcantly different
(2-year cumulative incidences of relapse in the CNSþAML
group and the CNSeAML group were 30.2% and 27.4%,
respectively [P ¼ .418] [Figure 2A], and the 2-year NRM rates
in the CNSþAML group and the CNSeAML group were 14.5%
and 22.0%, respectively [P ¼ .142] [Figure 2B]). Multivariate
analysis showed that CNS involvement did not affect OS
signiﬁcantly after adjusting for covariates (Table 2).
Outcome of Allo-HSCT for OS in the CNSþAML Group
Further analysis of the CNSþAML group was performed.
Six patients received CNS irradiation as part of the condi-
tioning regimen; their OS did not signiﬁcantly differ from
that of patients who did not receive CNS irradiation
(P ¼ .343). Multivariate analysis showed the development of
P = .847 P = .347
P = .941
P = .213
P = .936
Figure 1. Survival of patients stratiﬁed by CNS involvement. (A) OS of all patients in the study. (B) OS of patients grouped according to age at transplantation. (C) OS of
patients grouped according to disease status at transplantation.
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interval [CI], .232 to .956; P ¼ .037), non-CR at the time of
allo-HSCT (HR ¼ 4.11; 95% CI, 2.10 to 8.04; P < .001), and
intermediate (HR ¼ 4.185; 95% CI, 1.55 to 11.3; P ¼ .005) and
poor (HR ¼ 3.59; 95% CI, 1.32 to 9.79; P ¼ .012) cytogenetic
risk categories were independent prognostic factor for OS
(Table 3).
Forty-three patients developed relapse after allo-HSCT;
systemic relapse other than CNS and CNS relapse occurred
in 21 patients and 10 patients, respectively. The relapse site
was not known in 12 patients.Figure 2. Cumulative incidence of events after transplantation stratiﬁed by CNS inv
(B) Cumulative incidence of NRM of all patients.DISCUSSION
The current analysis showed the estimated OS, relapse,
and NRM rates were comparable in the CNSþAML and
CNSeAML groups. Although there were signiﬁcant differ-
ences in patient characteristics between the CNSþAML group
and the CNSeAML group, subgroup analyses according to
age, disease status, and cytogenetic risk category showed
similar results to those observed in the entire study popu-
lation. CNSþAML patients were signiﬁcantly younger than
CNSeAML patients; however, Figure 1B shows CNS involve-
ment did not affect transplantation outcome in both patientsolvement. (A) Cumulative incidence of relapse of patients who achieved CR.
Table 2
Univariate and Multivariate Analysis of OS in All Patients
Variables Risk Factors Univariate Multivariate
P HR 95% CI P
CNS
involvement
No .847 1
Yes 1.06 .806-1.40 .664
Age, yr <50 <.001 1
50 1.53 1.36-1.73 <.001
Gender Male <.001 1
Female .911 .822-1.01 .074
Disease status CR <.001 1
Non-CR 2.41 2.17-2.68 <.001
Donor source Related <.001 1
Unrelated
BM/PB
.945 .825-1.08 .414
Unrelated CB .82 .693-.971 .021
HLA match Match <.001 1
Mismatch 1.06 .913-1.23 .438
Conditioning
regimen
NoneTBI-
based MAC
<.001 1
TBI-based
MAC
1.09 .947-1.25 .231
RIC .979 .856-1.12 .757
Performance
status
0, 1 <.001 1
2-4 1.63 1.38-1.92 <.001
Cytogenetic
risk category
Favorable <.001 1
Intermediate .964 .811-1.15 .674
Unfavorable 1.35 1.13-1.61 <.001
Unknown 1.13 .907-1.41 .276
Acute GVHD No <.001 1
Yes 1.17 1.06-1.30 .003
Chronic GVHD No <.001 1
Yes .645 .574-.724 <.001
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Furthermore, multivariate analysis showed that CNS
involvement did not signiﬁcantly affect OS. These results
suggest that allo-HSCT may decrease the relapse rate and
overcome the poor prognosis otherwise associated with
CNSþAML. This notion is consistent with the observations of
Shihadeh et al. [3], in which 4 of 5 patients who survived for
more than 18 months received allo-HSCT. The clinical char-
acteristics of patients with CNSþAML in this study were
consistent with those seen in previous studies [3-5].
Mayadev et al. [12] and Bommer et al. [13] reported that
persistent CNS involvement at the time of allo-HSCT was
associated with dismal outocomes. However, the current
study included patients in CR at the time of allo-HSCT. These
differences of patient populations appear to be cause of the
discrepancy.Table 3
Univariate and Multivariate Analysis of OS in CNSþAML Patients
Variables Risk Factors Univariate Multivariate
P HR 95% CI P
Chronic GVHD No .024 1
Yes .471 .232-.956 .037
Disease status CR <.001 1
Non-CR 4.11 2.10-8.04 <.001
Performance
status
0, 1 <.001 1
2-4 1.86 .927-3.72 .082
Cytogenetic risk
category
Favorable .04 1
Intermediate 4.19 1.55-11.3 .005
Unfavorable 3.59 1.32-9.79 .012
Unknown 3.34 .640-17.4 .153The current analysis showed a signiﬁcantly higher
population of CNSþAML patients was in non-CR at the time
of allo-HSCT compared with CNSeAML patients. Further,
patients with CNSþAML in non-CR had poor outcomes,
similar to previous studies [12,13]. These results suggest that
additional therapy should be considered for these patients;
whereas the beneﬁt of intrathecal chemotherapy after allo-
HSCT as maintenance therapy is controversial [14-17], addi-
tional cranial irradiation for remaining CNS disease might
improve outcomes for AML patients after allo-HSCT [12].
Because only 6 patients received CNS irradiation as part of
the conditioning regimen in our cohort, we could not sufﬁ-
ciently evaluate the role of CNS irradiation. Therefore,
optimal additional treatment for patients with CNSþAML
remains unclear, and further study is necessary.
Because lumbar puncture and intrathecal prophylaxis are
not routinely performed in AML patients [18], CNS involve-
ment was not evaluated in all patients. However, the inci-
dence of CNS involvement is compatible with that seen in a
previous report [2]. Therefore, it is considered that our
cohort included a substantial proportion of those with
CNSþAML from the entire registry population.
The current analysis showed a higher proportion of
patients had worse Eastern Cooperative Oncology Group
performance status at allo-HSCT in the CNSþAML group
compared with the CNSeAML group. It may be suspected
that some CNSþAML patients could not receive allo-HSCT
due to poor performance status or severe comorbidity.
This analysis had some limitations. First, the data about
pretransplant therapy were lacking. The pretransplant ther-
apy for the CNSþAML group likely differed from that of the
CNSeAML group and contributes to the overall outcomes for
these patients, possibly with respect to relapse and NRM.
Second, the CNSþAML group only represents 3% of the entire
data set. Thus, there may not be enough power to detect a
small difference in outcomes between the CNSþAML and
CNSeAML groups.
In conclusion, our study showed that outcomes after
allo-HSCT were comparable in CNSþAML and CNSeAML
patients. Furthermore, the outcomes for patients in CR were
similar when comparing CNSþAML and CNSeAML patients.
To the best of our knowledge, the current nationwide
retrospective analysis included the largest number of pa-
tients with CNSþAMLwho have undergone allo-HSCT within
the published literature. Therefore, the current study may be
useful in deciding whether patients with CNSþAML should
undergo allo-HSCT.ACKNOWLEDGMENTS
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